Combining HDAC Inhibitors with N-Hydroxyurea for Polycythemia Vera
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Philadelphia-negative myeloproliferative syndromes, such as N-hydroxyurea, often result in poor tolerance and unsatisfactory therapeutic responses, with high doses required to manage side effects and a risk of thrombo-embolic events and disease progression.
Innovation Solution
Combining diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride with N-hydroxyurea, preferably in the monohydrate crystal form, to enhance treatment efficacy and reduce side effects in patients refractory to or poorly responding to N-hydroxyurea monotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If N-hydroxyurea is used at high doses to treat Philadelphia-negative myeloproliferative syndromes, then therapeutic response is improved, but side effects and patient tolerance worsen
Solution Approach 1:
The patent combines N-hydroxyurea with a histone deacetylase inhibitor (such as entinostat, panobinostat, or romidepsin) to create a synergistic therapeutic effect. This combination allows for reduced dosing of N-hydroxyurea while maintaining or improving therapeutic response, thereby reducing side effects and improving patient tolerance.
2Ease of operation
If N-hydroxyurea monotherapy is used to treat Philadelphia-negative myeloproliferative syndromes, then treatment simplicity is maintained, but therapeutic efficacy is insufficient for refractory patients
Solution Approach 1:
The patent introduces a combination therapy approach by merging N-hydroxyurea with histone deacetylase inhibitors. This combination specifically addresses refractory cases where monotherapy fails, improving therapeutic efficacy while maintaining a relatively simple treatment protocol through the use of established drugs with a reasonable safety profile.
3Reliability
If continuous N-hydroxyurea therapy is administered to prevent disease progression, then long-term disease control is achieved, but cumulative toxicity and patient quality of life worsen
Solution Approach 1:
The patent changes the therapeutic parameter by introducing histone deacetylase inhibitors with different mechanisms of action. This allows for effective disease control through synergistic action, enabling the use of lower doses of N-hydroxyurea and reducing cumulative toxicity while maintaining reliable long-term disease control.
Data Source
AI summary
Method for treating Philadelphia-negative myeloproliferative syndromes in a patient in need of such treatment, by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof, in combination with N-hydroxyurea.